Immunotherapy has been increasingly used in the treatment of solid tumors; by blocking immune checkpoints, anti-programmed cell death ligand 1 (PD-L1) therapy aims to disrupt immune tolerance mechanisms, reactivate T cells, and boost anti-tumor immunity. The gene discussed is CD274; the disease is neoplasm.